People · Operator
Named in public records as an officer, director or promoter · active 2013–2026 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Siduma Therapeutics, Inc. | — | Biotechnology | Series B | $31.2M | $686.3M | 2021 |
| Quarry Heme, Inc | — | Biotechnology | Series A | $13.5M | $32.9M | 2026 |
| Quarry Thera, LLC | — | Biotechnology | Series A | $5.0M | $19.3M | 2025 |
| Arvinas, Inc. | — | Pharmaceuticals | Seed | $3.5M | $133.6M | 2013 |
| Quarry DAC, Inc | — | Biotechnology | Seed | $2.1M | $4.2M | 2026 |
| Duracrin, LLC | — | Biotechnology | Pre-Seed | $1.0M | $1.7M | 2026 |
Craig Crews at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Craig Crews on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sean Cassidy | 3 | 7 |
| Kush Parmar | 1 | 10 |
| Timothy Shannon | 1 | 9 |
| Tim Shannon | 1 | 9 |
| Jonathan Soderstrom | 1 | 3 |
| Dan McHugh | 1 | 3 |
| Rebecca Frey | 1 | 2 |
| Mikael Dolsten | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.